Nifuradene (NF-246), a chemotherapeutic nitrofuran, was first synthesized and reported in 1956. Nifuradene, a 5-Nitorofuran derivative, is an antibacterial drug. Early in vitro testing found it an effective chemotherapeutic agent against most of the common urinary pathogens. Subsequent in vivo studies found that this compound is well absorbed after oral administration in both animals and humans. Nifuradene was used for the treatment of urinary tract infections. The over-all cure rate was found to be best at doses exceeding 600 mg a day.